Xilio Therapeutics, Inc., a clinical-stage biotechnology company, has provided financial guidance indicating a solid cash position. As of June 30, 2025, the company reported cash and cash equivalents totaling $121.6 million. With the recent achievement of a $17.5 million development milestone under its license agreement with Gilead Sciences, Inc., Xilio anticipates that this financial reserve will support its operating expenses and capital expenditure needs into the first quarter of 2027. The company expects to receive the payment for the milestone by the fourth quarter of 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xilio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9525574-en) on September 09, 2025, and is solely responsible for the information contained therein.